ESPR (Esperion Therapeutics) Moat Score: 3/10 (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ESPR Esperion Therapeutics Inc ESPR
62 GF Score
Price $3.18
GF Value $2.30
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Esperion Therapeutics Moat Score?

Esperion Therapeutics ESPR -0.31% 62 Moat Score is 3 as of Aug. 04, 2026. GuruFocus rates ESPR with a GF Score™ of 62/100 and a GF Value™ of $2.30 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Esperion Therapeutics ranks better than 86.01% on this metric.

Esperion Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Esperion Therapeutics has No Moat: Esperion Therapeutics Inc has some intellectual property in drug development, but faces intense competition and lacks significant market share. The company's pricing power and customer loyalty are weak, and it does not have durable cost advantages or regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Esperion Therapeutics might have No Moat - Very weak/transient advantages.

Esperion Therapeutics  (NAS:ESPR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Esperion Therapeutics Moat Score Related Terms

ESPR vs AMPH, NIKA, BIOA: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Esperion Therapeutics Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's Moat Score falls into.


ESPR
62GF Score
Esperion Therapeutics Inc ESPR
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Esperion Therapeutics (ESPR) has a Moat Score of 3 as of Aug. 04, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Esperion Therapeutics ranks #144 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 14%.
Is Esperion Therapeutics' Moat Score too high?
Esperion Therapeutics' current Moat Score is 3. Based on the distribution chart, Esperion Therapeutics ranks #144 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Esperion Therapeutics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Esperion Therapeutics' Moat Score compare to AMPH and NIKA?
According to the Drug Manufacturers industry distribution chart, Esperion Therapeutics ranks #144 out of 1029 companies for Moat Score. This places Esperion Therapeutics in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Esperion Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Esperion Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Esperion Therapeutics (ESPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.30, compared to a current price of $3.18 — trading 38.3% above its estimated fair value. The current Moat Score is 3. Esperion Therapeutics' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Esperion Therapeutics (ESPR), the current Moat Score is 3 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Esperion Therapeutics (ESPR) Overvalued in 2026?

Based on GuruFocus' analysis, Esperion Therapeutics stock appears to be overvalued. The current stock price of $3.18 is trading 38.3% above its estimated GF Value™ of $2.30. GuruFocus considers Esperion Therapeutics to be Significantly Overvalued.

Key valuation signals for ESPR:

  • Moat Score: 3
  • GF Value™: $2.30 vs. price of $3.18 (38.3% above fair value)
  • GF Score™: 62/100 with 6 warning signs

No single metric tells the full story. See the ESPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Esperion Therapeutics Business Description

Other Exchanges 0IIM:UK0ET:Germany
Address 3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
62GF Score

Get the complete analysis for ESPR

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.18
Price
$2.30
GF Value